The 12-month treatment with the oral contraceptiveformulation containing dienogest (DNG) andestradiol valerate (E2V) shows beneficial effects onpsychological symptoms: results from aprospective comparative study with a formulationcontaining ethinyl estradiol (EE) and drospirenone(DRSP)

The COCs evolution has been obtained with new and differents progestinic compounds associated with lower doses of EE (ethinylestradiol). The revolution in the COCs field is the introduction of estradiol valerate (E2V), ester of the natural estrogen, estradiol (E2) instead of EE. Dienogest (DNG) is the progestinic compound of the COC Klaira® associated with E2V in a multiphase formulation. DNG has a strong antiandrogenetic action without the mineralcorticoid and glucocorticoid action and E2V acts in this association improving the subjective sleep quality, somatic complaints, anxiety, vigilance, cognition and numerical memory. The EE/DRSP (drospirenone) association (Yaz®) has a progestinic compound characterized by antimineralcorticoid and antiandrogenic properties with a positive effect on psychological symptoms. In this prospective study we evaluated if E2V is able to exert the same psychological symptoms as EE/DRSP formulation. Psychological changes were evaluated with SCL90 for 5 cycles. In comparison with the basal value the score was significantly reduced (p<0,001) during both treatments. This effects observed confirm that DNG and DRSP act with beneficial effects on CNS